Application of pinocembrin to preparation of medicines for treating demyelination diseases

A technology for demyelinating diseases and therapeutic drugs, applied in the field of pharmaceutical preparations and pinine salts containing pinine, pinine precursor or pinine hydrate, can solve unclear problems and achieve relief from medical treatment cost, promotion of myelin sheath regeneration, effect of mature purification process

Active Publication Date: 2017-07-21
SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] Although some signaling pathways have been proven to mediate the pharmacological effects of pinoquinone, the research on the effect of pinoquinone on central glial cells has not been reported. Clearly, there are no literature reports on the association of pinoquinone with demyelinating diseases and multiple sclerosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of pinocembrin to preparation of medicines for treating demyelination diseases
  • Application of pinocembrin to preparation of medicines for treating demyelination diseases
  • Application of pinocembrin to preparation of medicines for treating demyelination diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] Example 1: The promotion effect of Pinustin (PB) on the differentiation of oligodendrocyte precursor cells (OPCs)

[0031] 1. Experimental method:

[0032] In order to study and confirm the effect of pininetin on the differentiation of OPCs, qRT-PCR, Western blot, and immunocytochemistry were used to confirm that pininetin can promote the differentiation and maturation of OPCs from the mRNA level, protein level and morphological level.

[0033] 1. Experimental cells: primary cultured oligodendrocyte precursor cells (OPCs).

[0034]2. Reagents and consumables commonly used in the experiment: DMEM culture medium and Neurobasal / B27 culture medium were purchased from Gibco Company in the United States; fetal bovine serum FBS was purchased from PAA Company in Australia; 0.25% Trypsin trypsin, L-polylysine (poly- L-lysine, PLL) was purchased from Sigma, USA; Trizol Reagent was purchased from Invitrogen. Other routine reagent materials in the laboratory were purchased from S...

Embodiment 2

[0053] Example 2: Pinustin does not affect cell proliferation and survival while promoting OPCs differentiation

[0054] 1. Experimental method:

[0055] In order to verify whether pinoquinone will affect other changes in cells while promoting OPCs differentiation, BrdU binding assay and TUNEL assay were used to study cell proliferation and apoptosis, reflecting the influence of drugs on cells from the two indicators.

[0056] 1. Experimental cells: primary cultured oligodendrocyte precursor cells (OPCs).

[0057] 2. Experimental reagents, consumables and instruments: DMEM culture medium, Neurobasal / B27 were purchased from Gibco, USA; fetal bovine serum FBS was purchased from PAA, Australia; 0.25% Trypsin, L-polylysine (poly-L -lysine, PLL) was purchased from Sigma, USA; Trizol Reagent was purchased from Invitrogen. Other routine reagent materials in the laboratory were purchased from Shanghai Sinopharm Group, and cell culture dishes and plates were purchased from Corning In...

Embodiment 3

[0069] Example 3: The promoting effect of pinoquinone on the functional restoration of EAE

[0070] 1. Experimental method:

[0071] Based on the results of in vitro experiments, in order to further verify the pharmacological effects of pinoquinone on the inflammation-induced demyelination model, we successfully induced the EAE animal model and administered it therapeutically. On the 10th day of MOG-induced EAE model, observed Dosing was started after the onset of symptoms in the mice, and the administration continued until the 25th day to evaluate whether the drug could treat / relieve the disease.

[0072] 1. Experimental animals: C57BL / 6J adult female mice were purchased from Shanghai Slack Company and Nanjing University Model Animal Center. All animal experiments were performed in accordance with the animal management regulations and ethical requirements of the Animal Management Committee of the Second Military Medical University of the Chinese People's Liberation Army.

...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the technical field of medicine, provides application of pinocembrin, pinocembrin salts, pinocembrin precursors or pinocembrin hydrates to preparation of medicines for treating demyelination diseases and further provides a pharmaceutical preparation for preventing or treating the demyelination diseases. The pharmaceutical preparation is composed of pinocembrin, pinocembrin salts, pinocembrin precursors or pinocembrin hydrates and pharmaceutically-acceptable auxiliary materials. By in-vitro pharmacodynamic experiments, pinocembrin is capable of promoting differentiation and maturation of oligodendrocyte precursor cells which are myelin sheath source cells in transcriptional level and protein level, myelin sheath related expression is increased, and certain dose dependency is shown; by in-vivo experiments, pinocembrin is capable of evidently alleviating animal disease process and disease severity and also has a remarkable inhibition effect on inflammatory cell infiltration and demyelination injuries and a remarkable effect of remyelination promotion, and a new basis is provided for treatment of the demyelination diseases and multiple sclerosis.

Description

technical field [0001] The invention belongs to the field of biomedicine, and specifically relates to the application of pinogenin in the preparation of medicines for treating demyelinating diseases, and pharmaceutical preparations containing pinogenin, pinogenin salts, pinogenin precursors or pinogenin hydrates. Background technique [0002] Nerve myelin sheath is an important structure to maintain normal nerve function, and has the functions of insulating, accelerating nerve potential conduction and protecting axons. Demyelinating damage to the central nervous system is widely present in mental and neurological diseases such as multiple sclerosis, neonatal periventricular softening, ischemic hypoxic encephalopathy, Alzheimer's disease, depression, etc. There is an urgent need to find an appropriate treatment strategy for definite and effective treatment. [0003] When demyelinating injury occurs, the body's own oligodendrocyte precursor cells (Oligodendrocyte Progenitor C...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/352A61P25/28A61P25/00
CPCA61K31/352
Inventor 何成曹莉刘明东浦颖艳
Owner SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap